a cmyc pe  (Novus Biologicals)

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: Caudal discs of SM/J mice evidence early cellular senescence and a senescence signature during degeneration. At four weeks of age, SM/J mice have increase abundance of senescence markers in their caudal discs, evidenced by ( a–a” ) p19 and ( b–b” ) p21 abundance relative to age-matched B6J discs. c Microarray analysis of 4-week-old and 17-week-old SM/J NP and AF shows distinct clustering in both tissues between the two timepoints. Thematic analysis in CompBio of enriched concepts in 17-week-old NP tissues, compared to 4-week-old tissues shows: ( d’ ) Beta-galactoside Alpha-2,3-sialytransferase Activity is an upregulated theme in the NP; ( e ) VEGF-A Complex is an upregulated theme in the AF; ( f ) CDK1 Phosphorylates Condensin is a downregulated theme in the NP; and ( g ) RUNX2 Regulates Osteoblast Differentiation is a downregulated theme in the AF. h Venn Diagram showing the gene-level overlap between SM/J tissue profiles and the SenMayo geneset, with the overlapping genes shown in ( i ). Data are shown as mean ± SD. Significance was determined using an unpaired t -test or Mann-Whitney test, as appropriate. n C57BL/6J 4w = 8; n SM/J 4w = 5; n SM/J 17w = 6

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Microarray, Activity Assay, MANN-WHITNEY

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: DQ reduces caudal disc degeneration and senescence in SM/J mice. a , b Schematic showing study design: intraperitoneal injections of DQ, Nav., or a Vehicle control were administered once every week to mice starting at 4 weeks of age and ending at 17 weeks of age. a’ –a’” SafraninO/Fast Green/Hematoxylin staining evaluated with modified Thompson scoring shows DQ improves disc degeneration in SM/J mice. Images reflect the range of degenerative outcomes across treatment cohorts. b’ –b” Safranin/Fast Green/Hematoxylin staining evaluated with modified Thompson scoring shows Nav. does not improve disc degeneration in SM/J mice. Quantitative immunohistochemistry shows reduced ( c–c” ) p19 (NP and AF) and ( d–d” ) p21 (AF only) in DQ-treated SM/J discs. SASP markers of ( e–e” ) TGF β, ( f–f” ) IL-6, ( g–g” ) MMP13, and ( h–h” ) IL-1β indicate DQ mediates SASP in SM/J discs. Data are shown as mean ± SD. Significance was determined using an unpaired t -test or Mann-Whitney test, as appropriate. Distribution statistics were determined using a χ 2 test. 17 weeks old ( n DQ = 11, 6 females + 5 males; n CT = 13, 6 females + 7 males; n Nav. = 7, n Veh. = 7)

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Control, Staining, Modification, Immunohistochemistry, MANN-WHITNEY

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: Caudal discs of SM/J mice evidence early cellular senescence and a senescence signature during degeneration. At four weeks of age, SM/J mice have increase abundance of senescence markers in their caudal discs, evidenced by ( a–a” ) p19 and ( b–b” ) p21 abundance relative to age-matched B6J discs. c Microarray analysis of 4-week-old and 17-week-old SM/J NP and AF shows distinct clustering in both tissues between the two timepoints. Thematic analysis in CompBio of enriched concepts in 17-week-old NP tissues, compared to 4-week-old tissues shows: ( d’ ) Beta-galactoside Alpha-2,3-sialytransferase Activity is an upregulated theme in the NP; ( e ) VEGF-A Complex is an upregulated theme in the AF; ( f ) CDK1 Phosphorylates Condensin is a downregulated theme in the NP; and ( g ) RUNX2 Regulates Osteoblast Differentiation is a downregulated theme in the AF. h Venn Diagram showing the gene-level overlap between SM/J tissue profiles and the SenMayo geneset, with the overlapping genes shown in ( i ). Data are shown as mean ± SD. Significance was determined using an unpaired t -test or Mann-Whitney test, as appropriate. n C57BL/6J 4w = 8; n SM/J 4w = 5; n SM/J 17w = 6

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Microarray, Activity Assay, MANN-WHITNEY

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: DQ reduces caudal disc degeneration and senescence in SM/J mice. a , b Schematic showing study design: intraperitoneal injections of DQ, Nav., or a Vehicle control were administered once every week to mice starting at 4 weeks of age and ending at 17 weeks of age. a’ –a’” SafraninO/Fast Green/Hematoxylin staining evaluated with modified Thompson scoring shows DQ improves disc degeneration in SM/J mice. Images reflect the range of degenerative outcomes across treatment cohorts. b’ –b” Safranin/Fast Green/Hematoxylin staining evaluated with modified Thompson scoring shows Nav. does not improve disc degeneration in SM/J mice. Quantitative immunohistochemistry shows reduced ( c–c” ) p19 (NP and AF) and ( d–d” ) p21 (AF only) in DQ-treated SM/J discs. SASP markers of ( e–e” ) TGF β, ( f–f” ) IL-6, ( g–g” ) MMP13, and ( h–h” ) IL-1β indicate DQ mediates SASP in SM/J discs. Data are shown as mean ± SD. Significance was determined using an unpaired t -test or Mann-Whitney test, as appropriate. Distribution statistics were determined using a χ 2 test. 17 weeks old ( n DQ = 11, 6 females + 5 males; n CT = 13, 6 females + 7 males; n Nav. = 7, n Veh. = 7)

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Control, Staining, Modification, Immunohistochemistry, MANN-WHITNEY

Journal: Bone Research

Article Title: Dasatinib and quercetin senolytic treatment delays early onset intervertebral disc degeneration in SM/J mice

doi: 10.1038/s41413-026-00526-4

Figure Lengend Snippet: JUN pathway inhibition mimics the positive effect of DQ in decreasing senescence and SASP in human degenerated NP cells. a Grade IV and V human degenerated NP cells show a lower percentage of β-Gal-staining after treatment with DQ and JUN inhibitor, or only DQ, respectively. b Grade IV Human NP cells exhibit lower expression of IL-6 , MMP2 , and MMP13 compared to the stimulus group. Additionally, DQ treatment resulted in a decrease in CDKN1A and IL-6 , while T5224 enhanced MMP13 expression. c Grade V human NP cells exhibit lower expression of CDKN1A, CDKN2A, IL-6 , CCL2 , MMP2 , and MMP13 relative to the stimulus group. DQ treatment attenuated the expression of IL-6 and CCL2 , and MMP2 . T5224 ameliorated CDKN1A , IL-6 , CCL2 , and MMP2 expression. Data are shown as mean ± SD. Significance was determined using Dunnett’s multiple comparisons test ( n = 3 independent experiments, performed in triplicate)

Article Snippet: Tissue sections were then blocked in 2%–10% normal serum in PBS-T, and incubated with antibodies against p19 (1:100, Novus NB200-106), p21 (1:200, Novus NB100-1941), collagen I (1:100, Abcam ab34710), aggrecan (1:50; Millipore; AB1031), chondroitin sulfate (1:300, Abcam ab11570), IL-1b (1:100, Novus NB600-633), IL-6 (1:50, Novus NB600-1131), TGFb (1:100; Abcam; ab92486), collagen X (1:500, Abcam ab58632), CA3 (1:150, Santa Cruz), and GLUT-1 (1:200, Abcam, ab40084).

Techniques: Inhibition, Staining, Expressing

Journal: Alzheimer's & Dementia : Translational Research & Clinical Interventions

Article Title: A potential multimodal biomarker – cognitive signature associated with the conversion from subjective cognitive decline to mild cognitive impairment

doi: 10.1002/trc2.70240

Figure Lengend Snippet: Characterization and imaging of serum‐derived cEVs. (A) cEVs images as acquired by transmission electron microscopy; bar represents 100 nm. (B) Concentration and size distribution of cEVs examined by NTA using Nanosight‐NS300. (C) ApoA1 concentration in serum and cEVs. (D) Immunoblot detection of EV protein markers and non‐associated proteins. The parametric Student's t ‐test was used for statistical analysis of ApoA1; *** p < 0.001. ALIX, ALG‐2‐interacting protein X; ApoA1, apolipoprotein A1; CD63, cluster of differentiation 63; cEVs, circulating extracellular vesicles; CTR, controls; nm, nanometer; NTA, nanoparticle tracking analysis; SCD, subjective cognitive decline; TSG101, tumor susceptibility gene 101.

Article Snippet: Proteins were incubated for 30 min with primary antibodies against TSG101 (Novus Biologicals LLC, Catalog No.: NB200–112, 1:10), CD63 (R&D Systems; Catalog No.: MAB50482, 1:20), ALIX (R&D Systems; Catalog No.: MAB50482, 1:20), and calnexin (Novus Biologicals LLC; Catalog No.: NB100–1965, 1:25), followed by washing and incubation with species‐specific secondary antibodies.

Techniques: Imaging, Derivative Assay, Transmission Assay, Electron Microscopy, Concentration Assay, Western Blot